| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,749 |
7,175 |
$409K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,338 |
2,611 |
$126K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,920 |
2,641 |
$94K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
6,329 |
4,460 |
$74K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,425 |
1,753 |
$61K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,787 |
1,182 |
$52K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
4,622 |
3,477 |
$48K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,047 |
1,466 |
$25K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
8,986 |
6,427 |
$22K |
| 99051 |
|
1,668 |
1,393 |
$17K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,380 |
1,740 |
$16K |
| 87428 |
|
500 |
372 |
$16K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,576 |
1,336 |
$14K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,010 |
1,487 |
$14K |
| 87634 |
|
601 |
467 |
$10K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
591 |
532 |
$10K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
298 |
236 |
$9K |
| 87631 |
|
159 |
145 |
$7K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
120 |
87 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
87 |
74 |
$2K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
87 |
56 |
$1K |
| 87420 |
|
151 |
131 |
$1K |
| 36416 |
|
5,086 |
3,278 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
48 |
30 |
$943.59 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
322 |
287 |
$797.03 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
600 |
451 |
$499.98 |
| 99201 |
|
27 |
23 |
$456.22 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,037 |
878 |
$383.20 |
| 85027 |
|
86 |
68 |
$363.26 |
| 81003 |
|
563 |
392 |
$323.35 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
39 |
30 |
$315.90 |
| 36415 |
Collection of venous blood by venipuncture |
165 |
114 |
$296.42 |
| 87581 |
|
12 |
12 |
$224.52 |
| 87486 |
|
12 |
12 |
$224.52 |
| 87529 |
|
18 |
13 |
$189.48 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
24 |
15 |
$168.75 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
18 |
13 |
$94.74 |
| 87511 |
|
18 |
13 |
$94.74 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
18 |
13 |
$94.74 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
12 |
12 |
$81.19 |
| 87640 |
|
38 |
28 |
$63.16 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
24 |
15 |
$56.25 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
18 |
13 |
$31.62 |
| 87653 |
|
16 |
12 |
$31.58 |
| 87481 |
|
16 |
12 |
$31.58 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
12 |
12 |
$24.44 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
15 |
13 |
$15.74 |
| 81025 |
|
21 |
12 |
$6.98 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
503 |
415 |
$0.00 |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
98 |
81 |
$0.00 |
| 94760 |
|
205 |
128 |
$0.00 |
| A9150 |
Non-prescription drugs |
40 |
26 |
$0.00 |